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Abstract 
In order to investigate the breast cancer prediction problem on the aging population with the 
grades of DCIS, we conduct a tree augmented naive Bayesian network experiment trained and 
tested on a large clinical dataset including consecutive diagnostic mammography examinations, 
consequent biopsy outcomes and related cancer registry records in the population of women 
across all ages. Our tasks are to classify the conventional “Benign vs. Malignant” and the new 
“Benign/LG vs. IntG/HG/Invasive” based on mammography examination features and patient 
demographic information, specifically to predict the probability of malignancy, for the biopsy 
threshold setting and the biopsy decision making. The aggregated results of our ten-fold cross 
validation method recommend a biopsy threshold higher than 2% for the aging population. The 
Receiver Operating Characteristic curves and the Precision-Recall curves by aggregating the 
ten-fold cross validation results are interesting. 
 
 
 
 
 
 
 
Introduction 
The practice of mammography in aging populations successfully diagnoses breast diseases 
including invasive cancers at an earlier stage. 1-2 However, the efficacy of mammography in 
older age groups can be affected substantially by inherent problems such as false-positive 3-4 
and over-diagnosis. 5 The false-positive problem leads to the problem of the high rate of breast 
biopsy: in the population of U.S. women older than 65 there are 140,000 breast biopsies cases 
per year, 6-7 75% of which turn out to be benign findings. Note that the procedure of breast 
biopsy is the most expensive component of breast cancer diagnosis. 8 These years the problem 
of the high rate of breast biopsy becomes more and more urgent: there are currently 21,784,000 
women over age 65 and the first of the baby boom generation born in the year 1946 has been 
aged over 65 since the year 2011; it is also projected that the number of women over age 65 will 
double and the number of women over age 85 will increase fivefold from the year 2000 to the 
year 2050. 9 
Another urgent problem emerges from the increasing rate of DCIS (ductal carcinoma in situ) 
which is a non-obligate precursor to subsequent invasive breast cancer. 10-11 DCIS, on one 
hand, typically appears as microcalcifications on mammography, whereas microcalcifications 
could be related to benign conditions including fibrocystic changes, a fibroadenoma, or fat 
necrosis. 12 The microcalcifications are often pursued with biopsy for diagnosis, which leads to a 
low positive predictive value of biopsy. As a result, the 2009 National Institutes of Health (NIH) 
consensus conference on DCIS urges the development of methodologies to more accurately 
identify subsets of women who might not need the treatment for DCIS 13 and whose risk of 
progression could be low enough to employ watchful waiting (mammographic evaluation at 
short term intervals) rather than breast biopsy. 14-15 
On the other hand, DCIS may remain indolent for sufficiently long that a woman dies of other 
causes. 16-17 Progression from DCIS to invasive breast cancer can be predicted by grades. 10,18-
19 Pathologists use three grading categories: grade 1 or “low grade” (LG), grade 2 or 
“intermediate grade” (IntG), and grade 3 or “high grade” (HG). 20 Study suggests that patients 
with DCIS of any grade are at increased risk for developing breast cancer, among which the 
interval is longest for the low grade. 10,17 Age adjusted incidence rate of DCIS between 1973 and 
2000 increased from 4.3 to 32.7 per 100,000 women-years, equivalent to an increase of 660%, 
21 the majority of which were detected on mammographic screening. 22 The increased rate of 
DCIS was most notable in the group of women over age 50. 23 Consequently, the NIH statement 
on DCIS highlighted the need for data and tools to improve management decisions. 13,24-25 The 
results of this conference were summarized as a “call to action” urging investigators to redouble 
efforts to determine optimal diagnosis and management of DCIS 24 and in turn prompted the 
Institute of Medicine to rank DCIS in the first quartile of topics to target comparative 
effectiveness research. 26 
The literature has confirmed that the patient demographic risk factors and the mammographic 
findings as described by radiologists according to the standardized lexicon, the Breast Imaging 
Reporting and Data System (BI-RADS) for mammogram feature distinctions and terminology, 
can predict the histology of breast cancer. 27-38 In order to investigate the breast cancer 
prediction problem on the aging population (the population of women over age 65) with the 
grades of DCIS, we conduct a tree augmented naive Bayesian network experiment trained and 
tested on a large clinical dataset including consecutive diagnostic mammography examinations, 
consequent biopsy outcomes and related cancer registry records in the population of women 
across all ages. The tasks of our experiment are to classify both the conventional task “Benign 
vs. Malignant” (“B vs. M”) and the new task “Benign/LG vs. IntG/HG/Invasive” (“B1 vs. M1”), 
based on mammography examination features. Note that the classifier “Malignant” in the 
conventional task “B vs. M” can be either DCIS or invasive cancer. Thus, although both the 
tasks can provide the “malignancy” (DCIS/Invasive and IntG/HG/Invasive, respectively) 
probabilities for the biopsy threshold setting and the biopsy decision making, the new task “B1 
vs. M1” can help investigate the breast cancer prediction with respect to the grades of DCIS. 
Methodology 
In general, a Bayesian network represents variables as “nodes”, which are data structures that 
contain an enumeration of possible values called “states” and store probabilities associated with 
each state, and conditional probabilities as “edges”. A naive Bayes model assumes that given 
the class variable, the value (“state”) of a particular feature variable is unrelated to the presence 
or absence of any other feature variable. Therefore in a naive Bayes model, the class variable is 
the “root node” and the directed arcs encode dependence relationships from the root node to 
the feature nodes. An important algorithm for naive Bayes model learning is to learn a tree 
structure to augment the edges of the naive Bayes network so as to produce a “tree augmented 
naive Bayesian network”. 39 Specifically, the algorithm firstly computes for each pair of feature 
variables the mutual information functions as the weights, secondly finds the maximum weight 
spanning tree and assign edge directions, and finally attaches the tree structure to the naive 
Bayes model to construct a tree augmented naive Bayesian network.  
Figure 1 presents a typical tree augmented naive Bayesian network trained for the task “B1 vs. 
M1” in the experiment. The root node, entitled “Benign/LG vs. IntG/HG/Invasive”, has two states 
that represent the outcome of interest—“Benign/LG” or “IntG/HG/Invasive”—and stores the prior 
probabilities of these states. The feature nodes in the network represent demographic risk 
factors, BI-RADS descriptors and the BI-RADS category. And the directed arcs encode the 
dependence relationships among the nodes, i.e. the conditional probabilities among the 
variables. Note that the nature of the tree augmented naive Bayes algorithm guarantees in a 
tree augmented naive Bayesian network, each feature node can have no more than one 
dependent node besides the root node.  
The tree augmented naive Bayesian network is trained and constructed on a large existing 
clinical dataset including consecutive diagnostic mammography examinations, consequent 
biopsy outcomes and related cancer registry records in the population of women across all 
ages. The consecutive diagnostic mammography examinations together with the patient 
demographic records provide the information of all the feature nodes; the root node information 
comes from the consequent biopsy outcomes and related cancer registry records; whereas the 
information of dependence relationships among the nodes is hidden in the database matching 
relations between the records of the consecutive diagnostic mammography examinations and 
the records of the consequent biopsy outcomes and related cancer registries. The model learns 
the probabilities within each node and discovers the arcs connecting the nodes to capture 
dependence relationships. As long as the Bayesian network’s predictive power is convincing in 
test, it can predict the posterior probability of malignancy for any new diagnostic mammography 
examination with patient demographic information.             
Experiment 
We conduct experiment on a large clinical dataset combined by the University of Wisconsin-
Madison Breast Imaging Database and the University of California San Francisco Breast 
Imaging Database. The UW database consists of screening and diagnostic mammography 
examinations at the UW Breast Imaging Center starting in October of 2005. As of 12/31/09, the 
database contains 41,682 mammography examinations on 24,510 patients described and 
recorded by the BI-RADS lexicon. The UCSF consists of 146,996 consecutive mammograms 
collected between 1/6/1997 and 6/29/2007. The combined dataset from UW and UCSF consists 
of 5607 consecutive diagnostic mammograms between 1/6/1997 and 12/27/2011 matched with 
following biopsy outcomes and corresponding cancer registries. 1729 cases are from UW 
database between 12/8/2005 and 12/27/2011 while 3878 cases are from UCSF database 
between 1/6/1997 and 6/29/2007.  
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As showed in the above pie graphs, the dataset contains 3569 benign cases, 1509 invasive 
cases, and 529 DCIS cases in which 134 are LG, 179 are IntG, and 216 are HG; among the 
1375 aging cases, the numbers of benign, invasive, DCIS, LG, IntG and HG cases are 636, 
577, 43, 49 and 70, respectively. The dataset reflects a fact of diagnostic mammograms: the 
aging population sees a higher rate of DCIS and a much higher rate of invasive breast cancer 
than the average. An interesting observation is that the proportions of each of the DCIS grades 
seem stable. 
For the experiment, we model the demographic risk factors and the mammogram features as 
feature nodes and the result of the biopsy outcome and/or the cancer registry as root node, 
follow the tree augmented naive Bayesian network algorithm to learn the probabilities and the 
structure from training datasets, and predict the malignancy probabilities on testing datasets.  
Table 1 makes a summary of all the variables in the experiment. Especially, the variable “Age 
Group” is one of our demographic risk factors, with the value “Older” representing the aging 
population. Most of mammograms in the dataset are assigned to the BI-RADS category 0, 4 and 
5. Many mammograms have “missing” values for the variable “Palpable Lump” (with value 
labels of “missing”, “No” and “Yes”), but the “missing” values for other mammogram feature 
variables simply mean “no such findings”. 
To label the biopsy outcome for the class variable, we used the most malignant result (Invasive 
> DCIS) and highest grade (HG > IntG > LG) at either core biopsy or subsequent surgery during 
the episode of care for analysis. The “episode of care” is defined as the duration of the process 
to definitively determine a breast diagnosis, including a core biopsy and subsequent diagnosis. 
A single diagnosis may entail more than one biopsy to determine the extent of disease or to 
confirm a benign diagnosis. This episode of care may entail multiple biopsies over an interval of 
time. For our purposes, we define an episode of care as 6 months. If 2 biopsies were performed 
in the same breast within 6 months of each other, we considered them as in the same episode.  
As the first step of the experiment, we prepare datasets for ten-fold cross validation: firstly 
randomly split the cases in each age group into ten equal-sized sets, each of which contains 
one-tenth of the benign findings, one-tenth of the invasive cancer findings and one-tenth of each 
of the grades of DCIS findings in that age group, along with the requirement that all records of 
the same patient be in the same set; secondly aggregate them into ten equal-sized folds of the 
whole population across all ages; and finally make ten pairs of training datasets and respective 
testing datasets. By using ten-fold cross validation, it is guaranteed that the cases used to train 
the model are never used to test the model. 
The second step is the implementation of the tree augmented naive Bayes algorithm. We use 
Weka (Waikato Environment for Knowledge Analysis) 40 for the training and testing of the tree 
augmented naive Bayesian network on the ten pairs of training datasets and respective testing 
datasets.  
Finally, from the output prediction files given by Weka in the implementation of the tree 
augmented naive Bayes algorithm for the training and testing of the tree augmented naive 
Bayesian network on the ten pairs of training datasets and respective testing datasets, we 
collect and aggregate the predicted malignancy probabilities on all the ten testing datasets. For 
the purpose of threshold analysis, for each of the 5001 possible breast biopsy thresholds, from 
0.00% to 100.00%, we assume no biopsy for the cases where the predicted malignancy 
probabilities are below that threshold and compute the confusion matrix results in EXCEL 
spreadsheet with VBA macros. For the aging population, we select and aggregate the predicted 
malignancy probabilities of all the aging cases and compute the confusion matrix results in the 
same way for each of the 2001 possible breast biopsy thresholds from 0.00% to 100.00%. 
In order to estimate the predictive performance of the tree augmented naive Bayesian network 
methodology in test, following the convention of the literature, 27-38 we construct the Receiver 
Operating Characteristic (ROC) curve and the Precision-Recall (PR) curve. The AUC which 
measures the area under the ROC curve is calculated. The AUCPR which measures the area 
under the PR curve is also meaningful 41-43 and is calculated as well. 
Result 
For the threshold analysis, Table 2 and Table 3 make snapshots of the confusion matrix results 
at typical thresholds in the whole population and in the aging population, respectively for the 
conventional task “B vs. M” and the new task “B1 vs. M1”. From the tables we can see there are 
always actual malignancy cases with low malignancy probabilities predicted by the tree 
augmented naive Bayesian network methodology, both in the whole population and in the aging 
population. In fact, our EXCEL spreadsheet also shows not a few non-malignancy cases with 
high malignancy probabilities predicted by the methodology. But considering the number of the 
cases in the dataset, from a probabilistic perspective, we conclude the results are acceptable. 
For the task “B vs. M”, if we set the breast biopsy threshold to be 1%, no malignancy case will 
be missed and 22 non-malignancy cases will avoid breast biopsies. Thus 1% is the “critical 
threshold” and for the task “B1 vs. M1” it will save 41 non-malignancy biopsies. However, any 
threshold above 1% means there will be a tradeoff between avoided non-malignancy biopsies 
and missed malignancy biopsies. For both tasks, the conventional threshold of 2% in the whole 
population seems convincing, in spite of the one missed invasive aging case. In the aging 
population, a threshold higher than 2% would be acceptable, due to the fact that if the threshold 
is lifted from 2% to 7%, the number of avoided non-malignancy biopsies would rise sharply 
while the number of missed malignancy biopsies would rise very slowly. 
Figure 2 constructs the comparable ROC curves for the conventional task “B vs. M” and the new 
task “B1 vs. M1”, respectively. Both the AUCs are approximately 0.84, whereas the new task 
yields a slightly larger one.  Figure 3 constructs the comparable PR curves for the conventional 
task “B vs. M” and the new task “B1 vs. M1”, respectively. The AUCPR of the conventional task 
exceeds that of the new task by 0.01. This observation that a larger AUC does not guarantee a 
larger AUCPR is consistent with the literature. 41-43 
It is interesting that the PR curve can be fitted very well by a third-order polynomial curve. The 
third-order polynomial regression of the Precision on the Recall yields an R-square of 0.9986 
with very significant regression parameters. We also find the relationship between the FPR 
(False Positive Rate) and the Precision can be fitted very well by a third-order polynomial curve. 
The third-order polynomial regression of the FPR on the Precision produces an R-square of 
0.9997 with very significant regression parameters. Figure 4 presents the curve fitting and the 
regression result of the PR curve. And Figure 5 presents the curve fitting and the regression 
result of the relationship between the FPR and the Precision. 
Summary 
One weakness of this experiment is that we aggregate the predicted malignancy probabilities on 
all the ten testing datasets to produce the threshold analysis and the ROC curve. This 
procedure is based on the assumption that the trainings of the tree augmented naive Bayesian 
network on the ten training datasets are the same. Although all the trainings follow the tree 
augmented naive Bayes algorithm, the differences among the ten training datasets which stem 
from the variance of data source, lead to different tree augmented naive Bayesian network 
structures and probabilities.  
Another weakness is that we make threshold analysis in the aging population using the tree 
augmented naive Bayesian networks trained by the cases across all ages. A more solid tree 
augmented naive Bayesian network experiment in the aging population should use only aging 
cases (women over age 65) for training and testing. 
In sum, we conduct a tree augmented naive Bayesian network experiment trained and tested on 
a large clinical dataset combined by the University of Wisconsin-Madison Breast Imaging 
Database and the University of California San Francisco Breast Imaging Database including 
consecutive diagnostic mammography examinations, consequent biopsy outcomes and related 
cancer registry records in the population of women across all ages. We classify the conventional 
task “Benign vs. Malignant” and the new task “Benign/LG vs. IntG/HG/Invasive” based on 
mammography examination features and patient demographic information. The aggregated 
predicted malignancy probabilities of our ten-fold cross validation method recommend a biopsy 
threshold higher than 2% for the aging population. The Receiver Operating Characteristic 
curves and the Precision-Recall curves by aggregating the ten-fold cross validation results are 
interesting. 
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Tables and Figures 
Table 1: summary statistics of the variables in the Tree Augmented Naive Bayesian network 
Variables         Instances         
31         5607         
Demographic                   
Age Group Younger Middle Older       
 2091 2141 1375       
Personal History No Yes 
      
  
  4697 910               
Family History None Minor Major missing 
    
  
  3888 1014 416 289           
Imaging                   
BIRADS Category 0 1 2 3 4 5 7 8 9 
  440 0 2 2 4513 650 0 0 0 
Breast Density       Predominantly Fatty   Scattered Fibroglandular   Heterogeneously Dense      Extremely Dense missing 
  484   2164   2384   574   1 
Mass Margin                   
Circumscribed missing present 
      
  
  4927 680 
      
  
Obscured missing present 
      
  
  5195 412 
      
  
Microlobulated missing present 
      
  
  5561 46 
      
  
Spiculated missing present 
      
  
  5116 491 
      
  
Indistinct missing present 
      
  
  4825 782               
Mass Shape                   
Oval missing present 
      
  
  5065 542 
      
  
Round missing present 
      
  
  5425 182 
      
  
Lobular missing present 
      
  
  5167 440 
      
  
Irregular missing present 
      
  
  5012 595               
Mass Density                   
Fat missing present 
      
  
  5598 9 
      
  
Low missing present 
      
  
  5578 29 
      
  
Equal missing present 
      
  
  5201 406 
      
  
High missing present 
      
  
  5373 234               
Calcification 
Morphology                   
Round missing present 
      
  
  5566 41 
      
  
Punctate missing present 
      
  
  5490 117 
      
  
Amorphous missing present 
      
  
  4950 657 
      
  
Pleomorphic missing present 
      
  
  4696 911 
      
  
Fine Linear missing present 
      
  
  5323 284               
Calcification 
Distribution                   
Diffuse missing present 
      
  
  5434 173 
      
  
Regional missing present 
      
  
  5576 31 
      
  
Clustered missing present 
      
  
  3693 1914 
      
  
Segmental missing present 
      
  
  5521 86 
      
  
Linear missing present 
      
  
  5441 166               
Asymmetric Density missing present 
      
  
  5116 491 
      
  
Architectural Distortion missing present 
      
  
  5140 467 
      
  
Palpable Lump missing No Yes 
     
  
  1376 2560 1671             
 
 
 
 
 
 
 
 
Table 2(a): typical biopsy thresholds and confusion matrix results for “B vs. M” in the whole population 
Biopsy 
threshold 
(%) 
Benign 
biopsies 
LG/IntG/HG/ 
Invasive 
biopsies 
Benign 
biopsies 
avoided 
LG 
biopsies 
missed 
IntG 
biopsies 
missed 
HG 
biopsies 
missed 
Invasive 
biopsies 
missed 
PPV Sensitivity Specificity 
Baseline 3569 2038 0 0 0 0 0 0.3635 1.0000 0.0000 
0.5 3567 2038 2 0 0 0 0 0.3636 1.0000 0.0006 
1.0 3547 2038 22 0 0 0 0 0.3649 1.0000 0.0062 
1.5 3495 2035 74 1 0 1 1 0.3680 0.9985 0.0207 
2.0 3437 2032 132 1 0 1 4 0.3715 0.9971 0.0370 
2.5 3371 2028 198 4 0 1 5 0.3756 0.9951 0.0555 
3.0 3295 2022 274 6 0 2 8 0.3803 0.9921 0.0768 
3.5 3224 2016 345 7 1 3 11 0.3847 0.9892 0.0967 
4.0 3140 2014 429 7 1 3 13 0.3908 0.9882 0.1202 
5.0 3022 2005 547 8 2 5 18 0.3988 0.9838 0.1533 
 
Table 2(b): typical biopsy thresholds and confusion matrix results for “B vs. M” in the aging population 
Biopsy 
threshold 
(%) 
Benign 
biopsies 
LG/IntG/HG/ 
Invasive 
biopsies 
Benign 
biopsies 
avoided 
LG 
biopsies 
missed 
IntG 
biopsies 
missed 
HG 
biopsies 
missed 
Invasive 
biopsies 
missed 
PPV Sensitivity Specificity 
Baseline 636 739 0 0 0 0 0 0.5375 1.0000 0.0000 
1.5 636 739 0 0 0 0 0 0.5375 1.0000 0.0000 
2.0 636 738 0 0 0 0 1 0.5371 0.9986 0.0000 
3.0 635 737 1 1 0 0 1 0.5372 0.9973 0.0016 
4.0 634 737 2 1 0 0 1 0.5376 0.9973 0.0031 
5.0 629 737 7 1 0 0 1 0.5395 0.9973 0.0110 
6.0 623 737 13 1 0 0 1 0.5419 0.9973 0.0204 
7.0 614 737 22 1 0 0 1 0.5455 0.9973 0.0346 
7.5 607 735 29 1 0 0 3 0.5477 0.9946 0.0456 
8.0 604 735 32 1 0 0 3 0.5489 0.9946 0.0503 
9.0 599 733 37 1 0 1 4 0.5503 0.9919 0.0582 
10.0 597 731 39 1 0 1 6 0.5505 0.9892 0.0613 
 
 
 
 
 
 
 
 
 
 
Table 3(a): typical biopsy thresholds and confusion matrix results for “B1 vs. M1” in the whole population 
Biopsy 
threshold 
(%) 
Benign/LG 
biopsies 
IntG/HG/ 
Invasive 
biopsies 
Benign 
biopsies 
avoided 
LG 
biopsies 
avoided 
IntG 
biopsies 
missed 
HG 
biopsies 
missed 
Invasive 
biopsies 
missed 
PPV Sensitivity Specificity 
Baseline 3703 1904 0 0 0 0 0 0.3396 1.0000 0.0000 
0.5 3699 1904 4 0 0 0 0 0.3398 1.0000 0.0011 
1.0 3662 1904 40 1 0 0 0 0.3421 1.0000 0.0111 
1.5 3598 1902 104 1 0 0 2 0.3458 0.9989 0.0284 
2.0 3517 1896 182 4 0 4 4 0.3503 0.9958 0.0502 
2.5 3425 1888 272 6 1 6 9 0.3554 0.9916 0.0751 
3.0 3343 1887 353 7 1 6 10 0.3608 0.9911 0.0972 
3.5 3269 1881 425 9 2 7 14 0.3652 0.9879 0.1172 
4.0 3186 1873 506 11 4 9 18 0.3702 0.9837 0.1396 
5.0 2977 1856 714 12 6 15 27 0.3840 0.9748 0.1961 
 
Table 3(b): typical biopsy thresholds and confusion matrix results for “B1 vs. M1” in the aging population 
Biopsy 
threshold 
(%) 
Benign/LG 
biopsies 
IntG/HG/ 
Invasive 
biopsies 
Benign 
biopsies 
avoided 
LG 
biopsies 
avoided 
IntG 
biopsies 
missed 
HG 
biopsies 
missed 
Invasive 
biopsies 
missed 
PPV Sensitivity Specificity 
Baseline 679 696 0 0 0 0 0 0.5062 1.0000 0.0000 
1.5 679 696 0 0 0 0 0 0.5062 1.0000 0.0000 
2.0 679 695 0 0 0 0 1 0.5058 0.9986 0.0000 
3.0 677 695 1 1 0 0 1 0.5066 0.9986 0.0029 
4.0 673 695 5 1 0 0 1 0.5080 0.9986 0.0088 
4.5 672 694 6 1 0 1 1 0.5081 0.9971 0.0103 
5.5 662 694 16 1 0 1 1 0.5118 0.9971 0.0250 
6.0 655 693 23 1 0 1 2 0.5141 0.9957 0.0353 
7.0 646 693 32 1 0 1 2 0.5176 0.9957 0.0486 
8.0 641 690 37 1 1 1 4 0.5184 0.9914 0.0560 
9.0 631 687 47 1 2 1 6 0.5212 0.9871 0.0707 
10.0 624 686 54 1 2 1 7 0.5237 0.9856 0.0810 
 
 
 Figure 1: A typical tree augmented naive Bayesian network trained for the task “B1 vs. M1” 
 Figure 2: ROC curve for “B vs. M” (AUC = 0.836) and ROC curve for “B1 vs. M1” (AUC = 0.842)  
 
 Figure 3: PR curve for “B vs. M” (AUCPR=0.781) and PR curve for “B1 vs. M1” (AUCPR=0.771) 
 
 Figure 4(a): Precision-Recall curve for “B1 vs. M1” and third-order polynomial curve fitting 
 
 Figure 4(b): Third-order polynomial regression of Precision on Recall for “B1 vs. M1” 
 
 
 Figure 5(a): FPR-Precision relationship for “B1 vs. M1” and third-order polynomial curve fitting 
 Figure 5(b): Third-order polynomial regression of FPR on Precision for “B1 vs. M1” 
